---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-000917"
form_type: "8-K"
ticker: "SBEV"
cik: "0001553788"
company_name: "SPLASH BEVERAGE GROUP, INC."
filed_at: "2026-07-06T20:30:33+00:00"
generated_at: "2026-07-06T20:32:23.386376+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Splash Beverage Group acquires exclusive worldwide license for CannEpil® epilepsy drug; issues $5.5M Series D preferred

## Summary
- Exclusive worldwide rights to CannEpil® (CBD/THC) for drug-resistant epilepsy; Licensor gets 15% royalty on net revenue.
- SBEV issues 5,500 shares of Series D Convertible Preferred (stated value $5.5M) to Licensor's noteholder as part of consideration.
- C/M Capital commits to invest at least $1M in SBEV within 60 days; also $1M sales bonus upon $5M cumulative net revenue.
- Development milestones: initiate Phase I trial within 24 months, Phase II within 48 months, file NDA after successful trials.
- Licensor may terminate if SBEV fails to obtain US regulatory approval within 5 years; initial term 20 years.

## SEC filing metadata
- accession: 0001731122-26-000917
- form_type: 8-K
- ticker: SBEV
- cik: 0001553788
- company_name: SPLASH BEVERAGE GROUP, INC.
- filed_at: 2026-07-06T20:30:33+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553788/000173112226000917/0001731122-26-000917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553788/000173112226000917/e7760_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-000917
- JSON: https://secwatch.observer/filing/0001731122-26-000917.json
- Plain text: https://secwatch.observer/filing/0001731122-26-000917.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.